These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37945141)

  • 1. Management of Intermediate-Stage Hepatocellular Carcinoma: Systemic Versus Locoregional Therapy.
    Patel M; Pillai A
    Surg Oncol Clin N Am; 2024 Jan; 33(1):159-172. PubMed ID: 37945141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress.
    Brown ZJ; Hewitt DB; Pawlik TM
    Expert Opin Investig Drugs; 2022 Apr; 31(4):379-391. PubMed ID: 34788184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials.
    Memon K; Kulik L; Lewandowski RJ; Gupta R; Ryu RK; Miller FH; Vouche M; Atassi R; Ganger D; Mulcahy MF; Salem R
    J Vasc Interv Radiol; 2013 Aug; 24(8):1189-1197.e2. PubMed ID: 23474327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic advances for patients with intermediate hepatocellular carcinoma.
    Sun JY; Yin T; Zhang XY; Lu XJ
    J Cell Physiol; 2019 Aug; 234(8):12116-12121. PubMed ID: 30648254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Image-guided percutaneous locoregional therapies for hepatocellular carcinoma.
    Chevallier O; Zhao K; Marinelli B; Yarmohammadi H
    Chin Clin Oncol; 2023 Apr; 12(2):17. PubMed ID: 37081710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate hepatocellular carcinoma: current treatments and future perspectives.
    Dufour JF; Bargellini I; De Maria N; De Simone P; Goulis I; Marinho RT
    Ann Oncol; 2013 Apr; 24 Suppl 2():ii24-9. PubMed ID: 23715940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Local and Systemic Therapies for Hepatocellular Cancer.
    Mokdad AA; Singal AG; Yopp AC
    Curr Oncol Rep; 2016 Feb; 18(2):9. PubMed ID: 26769114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit.
    Lee JJX; Tai DW; Choo SP
    ESMO Open; 2021 Jun; 6(3):100129. PubMed ID: 33887687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of hepatocellular in the United States.
    Mokdad AA; Hester CA; Singal AG; Yopp AC
    Chin Clin Oncol; 2017 Apr; 6(2):21. PubMed ID: 28482674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy.
    Yaghmai V; Besa C; Kim E; Gatlin JL; Siddiqui NA; Taouli B
    AJR Am J Roentgenol; 2013 Jul; 201(1):80-96. PubMed ID: 23789661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
    Lencioni R
    Crit Rev Oncol Hematol; 2012 Aug; 83(2):216-24. PubMed ID: 22142656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    Kis B; El-Haddad G; Sheth RA; Parikh NS; Ganguli S; Shyn PB; Choi J; Brown KT
    Cancer Control; 2017; 24(3):1073274817729244. PubMed ID: 28975829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
    Choi JY
    Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Hepatocellular Carcinoma: Current Status and Future Directions.
    Au JS; Frenette CT
    Gut Liver; 2015 Jul; 9(4):437-48. PubMed ID: 26087860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic approaches in intermediate-stage hepatocellular carcinoma (HCC): a novel insight of adjuvant transarterial chemoembolization (TACE).
    Fernández-Palanca P; Mauriz JL
    Chin Clin Oncol; 2023 Apr; 12(2):11. PubMed ID: 37038055
    [No Abstract]   [Full Text] [Related]  

  • 18. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
    Kim DY; Han KH
    Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.
    Han KH; Kudo M; Ye SL; Choi JY; Poon RT; Seong J; Park JW; Ichida T; Chung JW; Chow P; Cheng AL
    Oncology; 2011; 81 Suppl 1():158-64. PubMed ID: 22212951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review.
    Alnammi M; Wortman J; Therrien J; Afnan J
    Abdom Radiol (NY); 2022 Jul; 47(7):2299-2313. PubMed ID: 35524803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.